Logo

Sanofi's Sarclisa (isatuximab-irfc) Receives the US FDA's Approval for Relapsed Refractory Multiple Myeloma

Share this

Sanofi's Sarclisa (isatuximab-irfc) Receives the US FDA's Approval for Relapsed Refractory Multiple Myeloma

Shots:

  • The approval is based on P-III ICARIA-MM study Sarclisa (IV- 10mg/kg) + pomalidomide + dexamethasone (pom-dex) vs pom-dex as monothx. in patients with RRMM- prior treated with at least two therapies including lenalidomide and a proteasome inhibitor
  • The P-III ICARIA-MM study results: improvement in PFS (11.53 vs 6.47); improvement in ORR (60.4% vs 35.3%)
  • Sarclisa is mAb targeting CD38 receptor on MM cells- act by inducing apoptosis & immunomodulatory activity and has received FDA & EMA’s ODD with its anticipated availability in the US soon

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Pinterest


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions